Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 6, 2025Frontiers in MedicineOpen Access

Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoqian ZhaoJXJian XiongDLDanyang Li

Discussion

Loading...

Member takes

Overview

Mini review reveals translational advances in CAR T-cell and NK cell therapies for solid tumors, highlighting nanoparticle strategies.

Key Points

  • CAR T-cell and NK cell therapies have improved outcomes in hematological malignancies.
  • Nanoparticles enhance immune cell functionality and improve therapeutic delivery in solid tumors.
  • Current clinical trials face regulatory challenges and limitations in design rationales.
  • Advancements in nanotechnology may address key hurdles in immunotherapy translation.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/689a0fa0e6551bb0af8d1770https://doi.org/10.3389/fmed.2025.1655693
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Innovative strategies for improving CAR-T cell therapy: A nanomedicine perspective2025
  2. 2CAR NK cell therapy for solid tumors: potential and challenges2025
  3. 3CAR-exosomes derived from immune cells: an emerging nanoscale vanguard in overcoming tumor immunotherapy hurdles2025
  4. 4CAR-NK cell therapy in hematologic malignancies (2019–2025): A systematic review2025 · 3 citations
  5. 5Precision sniper for solid tumors: CAR-NK cell therapy2025 · 15 citations